A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01813448
- Locations
- 🇺🇸
Parexel, Glendale, California, United States
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01809860
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01780844
- Locations
- 🇺🇸
Site US10038, Pittsburgh, Pennsylvania, United States
🇺🇸Site US10007, Atlanta, Georgia, United States
🇺🇸Site US10018, Chicago, Illinois, United States
A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2012-10-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01711489
- Locations
- 🇺🇸
Parexel International, LLC, Glendale, California, United States
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2012-10-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01711827
- Locations
- 🇺🇸
Parexel International, LLC, Glendale, California, United States
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 611
- Registration Number
- NCT01711814
- Locations
- 🇧🇪
Site BE3314, Brussels, Belgium
🇨🇴Site CO3297, Bogota, Colombia
🇵🇱Site PL3603, Krakow, Poland
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01705483
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K
- Conditions
- Interventions
- First Posted Date
- 2012-09-17
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01686217
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01678287
- Locations
- 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01671774
- Locations
- 🇱🇻
Riga East University Hospital, LLC, Latvian Oncology Center, Riga, Latvia
🇩🇪Leipzig University Hospital, University Cancer Center (UCCL), Leipzig, Germany
🇩🇪Institut für Klinische Forschung, Krankenhaus Nordwest GmbH, Frankfurt, Hessen, Germany